ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1660

Digital Psychological Support for Inflammatory Rheumatic Diseases: A Randomized Clinical Trial

Johannes Knitza1, Julia Kraus2, Martin Krusche3, Isabell Haase3, Philipp Klemm4, Axel Hueber5, Pfeil Alexander6, Ulrich Drott7, Sebastian Kuhn8 and Jan Philipp Klein9, 1Institute for Digital Medicine, University Hospital Gießen-Marburg, Philipps University, Marburg, Germany, 2Vila Health, Berlin, Germany, 3Division of Rheumatology and Systemic Inflammatory Diseases, III. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 4Department of Rheumatology and Clinical Immunology Center, JLU Giessen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, 5Klinikum Nuernberg, Nuernberg, Germany, 6Department of Internal Medicine III, Jena University Hospital - Friedrich Schiller University Jena, Jena, Germany, 7Deutsches Endokrinologisches Versorgungszentrum, Frankfurt, Germany, 8Institute for Digital Medicine, University Hospital of Giessen and Marburg, Philipps University Marburg, Marburg, Germany, 9Department of Psychiatry, Psychosomatics and Psychotherapy, University of Lübeck, Lübeck, Germany

Meeting: ACR Convergence 2025

Keywords: Access to care, Anxiety, mental health, quality of life, Randomized Trial

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 27, 2025

Title: Abstracts: Health Services Research (1656–1661)

Session Type: Abstract Session

Session Time: 2:00PM-2:15PM

Background/Purpose: Patients with inflammatory rheumatic diseases (IRDs) frequently experience psychological distress, however access to psychological support remains limited. The aim of this trial (DRKS identifier: DRKS00032862) was to investigate the effectiveness of a digital psychological intervention for individuals with IRDs.

Methods: Participants aged 18 years or older were recruited across Germany between February 22, 2024 and June 4, 2024 if they had been diagnosed with rheumatoid arthritis (RA), psoriatic arthritis (PsA), or systemic lupus erythematosus (SLE) and reported psychological distress and reduced quality of life. Participants were randomized to either a self-guided digital psychological intervention or a treatment as usual control condition. The primary outcomes were change in psychological distress (Hospital Anxiety and Depression Scale [HADS]) and quality of life (Assessment of Quality of Life [AQoL-8D]) from baseline to three months. Secondary outcomes included changes in self-efficacy, health literacy, perceived stress, functional impairment, depression and anxiety.

Results: A total of 102 participants (mean [SD] age, 47.2 [12.9] years; 92 [90.2%] female; see Table 1) were randomized to the intervention group (n = 52) and the control group (n = 50) (Fig.1). The intervention group showed a significantly greater reduction in psychological distress at the 3-month follow-up (least squares mean difference, −3.60; 95% CI, −5.73 to −1.47; P < .001; Cohen’s d = -0.71), and a greater improvement of quality of life (least squares mean difference, 0.04; 95% CI, 0.00 to 0.09; P = .047; Cohen’s d = 0.49) (Fig.2). A significantly greater proportion of participants in the intervention group experienced a clinically meaningful improvement in psychological distress (59.2% vs. 34.0%, P = .016) and quality of life (55.1% vs 32.0%, P = .026) compared to the control group. Secondary outcomes measures showed a similar pattern of improvement, except for functional impairment. No adverse events related to the intervention were reported.

Conclusion: This randomized clinical trial supports the effectiveness and safety of a digital psychological intervention in individuals with IRDs. These findings suggest that such digital interventions could be a valuable, scalable approach to addressing mental health needs in rheumatology.

Supporting image 1Figure 1. Trial Participant Flow Diagram

Supporting image 2Figure 2. Least-squares Mean Changes of Primary Outcome Measures

Supporting image 3Table 1. Baseline Characteristics (Intention-to-Treat Sample)


Disclosures: J. Knitza: GAIA, 2, Vila Health, 12,, 2; J. Kraus: Vila Health, 3; M. Krusche: None; I. Haase: None; P. Klemm: None; A. Hueber: AbbVie, 2, 5, 6, Amgen, 2, 5, 6, Boehringer-Ingelheim, 2, 5, 6, Bristol-Myers Squibb(BMS), 2, 5, 6, Eli Lilly, 2, 5, 6, Galapagos/Alfasigma, 2, 5, 6, GlaxoSmithKlein(GSK), 2, 5, 6, Janssen, 2, 5, 6, Novartis, 2, 5, 6, Pfizer, 2, 5, 6, UCB, 2, 5, 6; P. Alexander: None; U. Drott: None; S. Kuhn: None; J. Klein: all about me, 2, Boehringer-Ingelheim, 2, Ethypharma, 2, GAIA, 2, 6, medac, 2, Oberberg, 6, Servier, 6, Stillachhaus, 6, sympatient, 2.

To cite this abstract in AMA style:

Knitza J, Kraus J, Krusche M, Haase I, Klemm P, Hueber A, Alexander P, Drott U, Kuhn S, Klein J. Digital Psychological Support for Inflammatory Rheumatic Diseases: A Randomized Clinical Trial [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/digital-psychological-support-for-inflammatory-rheumatic-diseases-a-randomized-clinical-trial/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/digital-psychological-support-for-inflammatory-rheumatic-diseases-a-randomized-clinical-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology